 |
- Conditions: Eye Diseases; Eye Infections; Eye Inflammation
Intervention: Device: Binocular OCT
Sponsors: University College, London; National Institute for Health Research, United Kingdom
Recruiting - Conditions: Dry Eye; Dry Eye Syndrome; Blepharitis; Meibomian Gland Dysfunction; Eye Pain; Punctate Epithelial Keratitis; Punctate Keratitis; Tear Film Insufficiency; Kerato Conjunctivitis Sicca; Eye Diseases
Intervention: Device: Artificial tears (classified by MHRA as a medical device)
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Fight for Sight
Recruiting - Condition: Dry Eye Disease
Intervention: Other: Propylene glycol-based eye drops
Sponsor: Novartis Pharmaceuticals
Recruiting - Conditions: Cataract; Age Related Macular Degeneration; Pseudophakia; Macular Disease; Diabetic Retinopathy; Retinal Disease
Intervention: Diagnostic Test: polarization sensitivity
Sponsors: South Warwickshire NHS Foundation Trust; Aston University
Recruiting - Condition: Open Angle Glaucoma
Interventions: Device: Direct Selective Trabeculoplasty; Device: Selective Trabeculoplasty
Sponsors: Belkin Laser Ltd.; European Commission; Universita degli Studi di Genova; Queen's University, Belfast
Recruiting - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Semaglutide; Drug: Placebo (semaglutide)
Sponsor: Novo Nordisk A/S
Recruiting - Conditions: Retinal Disease; Retinal Degeneration; Retinal Dystrophies
Intervention: Device: Long-wavelength autofluorescence imaging
Sponsor: Oxford University Hospitals NHS Trust
Not yet recruiting - Conditions: Dry Age-related Macular Degeneration; Macular Degeneration; Retinal Disease; Eye Diseases; Retinal Degeneration; Geographic Atrophy; Macular Atrophy
Intervention: Biological: GT005
Sponsor: Gyroscope Therapeutics
Recruiting - Condition: Diabetic Retinopathy
Interventions: Drug: BI 1467335; Drug: Placebo
Sponsor: Boehringer Ingelheim
Recruiting - Condition: Aphakia
Intervention: Device: Softec HP1 Intraocular Lens
Sponsor: Lenstec Incorporated
Not yet recruiting - Condition: Keratoconus
Intervention: Procedure: Customised CXL
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting - Condition: Keratoconus
Intervention: Procedure: Corneal Cross-linking
Sponsor: University of Plymouth
Recruiting - Condition: Retinal Detachment
Intervention:
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting - Condition: Cataract
Intervention: Device: Binocular-OCT
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting - Conditions: Myopia; Refractive Errors
Interventions: Procedure: Small incision lenticule extraction; Drug: Tobramycin and dexamethasone; Drug: Ofloxacin; Drug: Proxymetacaine 0.5%; Drug: Oxybuprocaine 0.4%
Sponsor: London Vision Clinic
Recruiting - Condition: Cataract
Intervention: Device: EyeCee One intraocular lens
Sponsor: University of Plymouth
Recruiting - Condition: Corneal Astigmatism
Interventions: Device: Toric intraocular MX60T lens; Other: Standard MX60 plus corneal incisions
Sponsors: Ashford and St. Peter's Hospitals NHS Trust; Bausch & Lomb Incorporated
Recruiting - Condition: Corneal Astigmatism
Interventions: Procedure: Trans-epithelial PTK; Device: EpiMaster Application Software
Sponsors: London Vision Clinic; Carl Zeiss Meditec AG; Optana GmbH
Not yet recruiting - Condition: Cataract
Interventions: Device: T-flex Aspheric Toric IOL; Device: AT TORBI toric IOL
Sponsors: University of Plymouth; BMI Southend Hospital
Recruiting - Condition: Non-syndromic Retinitis Pigmentosa
Intervention: Combination Product: Gene therapy: GS030-DP AND Medical device: GS030-MD
Sponsor: GenSight Biologics
Recruiting - Conditions: Keratoconus; Fuchs Dystrophy; Corneal Disease
Interventions: Procedure: Femtosecond Laser; Procedure: Trephine blade
Sponsor: University of Southampton
Recruiting - Condition: AMD
Interventions: Diagnostic Test: OCT; Diagnostic Test: Visual Acuity
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; National Institute for Health Research, United Kingdom; Newcastle University; Cardiff University; City, University of London; King's College London; Manchester University NHS Foundation Trust; University Hospitals Bristol NHS Foundation Trust; York Teaching Hospitals NHS Foundation Trust; Leeds Teaching Hospital NHS Foundation Trust; Bradford Teaching Hospitals NHS Foundation Trust; University College, London
Not yet recruiting - Condition: Age Related Macular Degeneration
Interventions: Drug: Ranibizumab; Drug: Aflibercept
Sponsors: King's College Hospital NHS Trust; King's College London
Recruiting - Condition: Myopia
Interventions: Drug: Atropine Sulfate; Other: Placebo
Sponsor: Belfast Health and Social Care Trust
Not yet recruiting - Condition: Wet Age-related Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, BAY86-5321)
Sponsor: Bayer
Not yet recruiting - Condition: Non-infectious Uveitis
Intervention: Biological: pEYS606
Sponsor: EYEVENSYS S.A.S.
Recruiting - Condition: Ocular Surface Disease
Intervention: Other: Autologous blood applied to dry eye
Sponsors: NHS Lanarkshire; Chief Scientist Office of the Scottish Government; NHS Research Scotland
Recruiting - Condition: Strabismus
Intervention:
Sponsors: Royal Liverpool and Broadgreen University Hospitals NHS Trust; Manchester University NHS Foundation Trust
Recruiting - Conditions: Epiretinal Membrane; Retinal Hemorrhage
Intervention: Device: Robot assisted surgery
Sponsor: University of Oxford
Recruiting - Condition: Optokinetic Nystagmus
Intervention: Device: CAVA
Sponsors: Emily Woodhouse; University of East Anglia; Medical Research Council
Recruiting - Condition: Age- Related Macular Degeneration
Intervention: Drug: Minocycline
Sponsor: National Eye Institute (NEI)
Recruiting - Condition: Vision, Low
Interventions: Device: MED; Other: Buddy
Sponsors: University of Manchester; City, University of London; Schepens Eye Research Institute
Recruiting - Safety and Efficacy of a Sub-epitheilal Transform™ Corneal Allograft (TCA) for Presbyopia CorrectionConditions: Presbyopia; Refractive Errors
Intervention: Other: Sub-epitheilal TCA Inlay
Sponsor: Allotex, Inc.
Not yet recruiting - Condition: Wet Macular Degeneration
Interventions: Drug: Faricimab; Drug: Aflibercept; Drug: Sham Procedure
Sponsor: Hoffmann-La Roche
Recruiting - Conditions: AMD; Diabetic Retinopathy; Retinal Degeneration; Retinal Dystrophies
Intervention: Device: Combined Coaxial Optical Coherence Tomography
Sponsor: Moorfields Eye Hospital NHS Foundation Trust
Recruiting - Condition: Wolfram Syndrome
Interventions: Drug: Sodium Valproate 200Mg E/C Tablet; Drug: Sodium Valproate matched placebo
Sponsor: University of Birmingham
Recruiting - Conditions: Uveitis; JIA
Interventions: Biological: Adalimumab; Other: Placebo
Sponsors: Nisha Acharya; Children's Hospital of Philadelphia; Children's Hospital Medical Center, Cincinnati; Children's Mercy Hospital Kansas City; National Eye Institute (NEI); Great Ormond Street Hospital for Children NHS Foundation Trust; University Hospitals Bristol NHS Foundation Trust; Alder Hey Children's NHS Foundation Trust; Johns Hopkins University; Children's Hospital Los Angeles; Seattle Children's Hospital; Newcastle-upon-Tyne Hospitals NHS Trust; University Hospital Southampton NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; The Royal Children's Hospital
Not yet recruiting - Condition: Uveitis
Interventions: Biological: Adalimumab (ADA); Drug: Conventional immunosuppression (CON)
Sponsor: JHSPH Center for Clinical Trials
Not yet recruiting - Condition: Noninfectious Uveitis
Interventions: Drug: Filgotinib; Drug: Placebo to match filgotinib; Drug: Prednisone
Sponsor: Gilead Sciences
Recruiting - Condition: Glaucoma, Angle-Closure
Intervention: Device: XEN45
Sponsor: Allergan
Recruiting - Condition: Open Angle Glaucoma and Cataract
Intervention: Drug: Prostaglandins
Sponsor: Emily Woodhouse
Recruiting - Condition: Glaucoma
Intervention:
Sponsor: Allergan
Recruiting - Condition: Hyperopia
Intervention: Other: Intrastromal TCA Inlay
Sponsor: Allotex, Inc.
Not yet recruiting - Condition: Presbyopia
Intervention: Other: TCA Intrastromal Inlay
Sponsor: Allotex, Inc.
Not yet recruiting - Condition: Leber Hereditary Optic Neuropathy
Intervention: Other: Patient-reported outcomes (PROs)
Sponsor: GenSight Biologics
Recruiting - Condition: Amblyopia
Intervention: Diagnostic Test: Visual acuity tests
Sponsor: Anglia Ruskin University
Recruiting - Condition: Non-infectious Uveitis
Intervention: Drug: PP-001
Sponsor: Panoptes Pharma GmbH
Recruiting - Condition: Leber Hereditary Optic Neuropathy
Interventions: Genetic: GS010; Drug: Placebo
Sponsor: GenSight Biologics
Recruiting - Condition: Achromatopsia
Intervention: Biological: AAV- CNGA3
Sponsor: MeiraGTx UK II Ltd
Not yet recruiting - Conditions: Hyperopia; Amblyopia; Anisohyperopia
Interventions: Device: Multifocal contact lenses; Device: Single vision contact lenses
Sponsors: Aston University; College of Optometrists
Recruiting - Conditions: Vision Disorders; Reading Disabilities
Interventions: Device: Precision tinted lenses; Device: Non-beneficial tinted lenses
Sponsor: City, University of London
Recruiting - Conditions: Neurofibromatosis Type 1; Plexiform Neurofibroma; Optic Nerve Glioma
Intervention: Drug: Selumetinib
Sponsors: Great Ormond Street Hospital for Children NHS Foundation Trust; AstraZeneca
Not yet recruiting - Condition: Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions: Radiation: Stereotactic radiotherapy (16 Gray or Sham); Drug: 0.5 mg ranibizumab
Sponsors: King's College Hospital NHS Trust; King's College London
Recruiting - Conditions: Open Angle Glaucoma; Ocular Hypertension
Interventions: Drug: Netarsudil/Latanoprost 0.02%/0.005%; Drug: GANFORT®
Sponsor: Aerie Pharmaceuticals
Recruiting - Conditions: Glaucoma, Open-Angle; Ocular Hypertension
Interventions: Drug: Bimatoprost SR; Drug: Sham Bimatoprost SR; Procedure: Selective Laser Trabeculoplasty; Procedure: Sham Selective Laser Trabeculoplasty
Sponsor: Allergan
Recruiting - Condition: Age Related Macular Degeneration (AMD)
Intervention: Other: No intervention
Sponsors: Frank G. Holz; Bayer; Moorfields Eye Hospital NHS Foundation Trust; Novartis Pharmaceuticals; Association for Innovation and Biomedical Research on Light and Image; City, University of London; European Clinical Research Infrastructure Network; La Fondation Voir et Entendre; Hoffmann-La Roche; Radboud University; University of Sheffield; University College, London; Carl Zeiss Meditec AG; Innovative Medicines Initiative
Recruiting - Condition: Dry Age-related Macular Degeneration
Interventions: Device: Valeda PBM treatment; Device: Valeda Sham treatment
Sponsor: LumiThera, Inc.
Recruiting - Condition: Diabetic Macular Edema
Interventions: Procedure: Diode 577 nm subthreshold micropulse laser; Procedure: Standard threshold laser (532 nm laser)
Sponsors: Belfast Health and Social Care Trust; Northern Ireland Clinical Trials Unit
Recruiting - Condition: Diabetic Macular Edema
Interventions: Drug: Aflibercept; Drug: Faricimab; Drug: Sham Procedure
Sponsor: Hoffmann-La Roche
Recruiting - Condition: Choroideremia
Intervention:
Sponsor: Nightstar Therapeutics
Recruiting - Condition: X-Linked Retinitis Pigmentosa
Intervention: Biological: AAV8-RPGR
Sponsor: Nightstar Therapeutics
Recruiting - Conditions: Dry Age-related Macular Degeneration; Macular Degeneration; Retinal Disease; Retinal Degeneration; Geographic Atrophy; Macular Atrophy
Intervention:
Sponsor: Gyroscope Therapeutics
Recruiting - Conditions: Health; Hypertension; Chronic Kidney Disease
Intervention:
Sponsor: University of Edinburgh
Recruiting - Condition: Choroideremia
Intervention: Genetic: AAV2-REP1
Sponsor: Nightstar Therapeutics
Recruiting - Condition: Acanthamoeba Keratitis
Interventions: Drug: PHMB 0.08%; Drug: Propamidine 0.1%; Drug: placebo; Drug: PHMB 0.02%
Sponsor: SIFI SpA
Recruiting - Condition: Retinopathy of Prematurity
Intervention: Drug: Ranibizumab
Sponsor: Novartis Pharmaceuticals
Recruiting - Conditions: Uveitis; Macular Edema
Interventions: Drug: Dexamethasone intravitreal implant 0.7 mg; Drug: Intravitreal Methotrexate 400 µg; Drug: Intravitreal Ranibizumab 0.5 mg
Sponsors: JHSPH Center for Clinical Trials; National Eye Institute (NEI)
Recruiting - Condition: Diabetic Retinopathy
Interventions: Drug: Fenofibrate 145 mg; Drug: Placebo Oral Tablet
Sponsors: University of Oxford; National Institute for Health Research, United Kingdom; University of Glasgow; University of Aberdeen; University of Dundee; University of Edinburgh; NHS Scotland Diabetic Retinopathy Screening Collaborative
Recruiting - Condition: Primary Sjogren's Syndrome
Interventions: Biological: VAY736; Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - Condition: Uveal Melanoma
Interventions: Biological: IMCgp100; Drug: Dacarbazine; Biological: Ipilimumab; Biological: Pembrolizumab
Sponsor: Immunocore Ltd
Recruiting - Conditions: Adenovirus; Anesthesia; Anxiety; Anxiolysis; Autism; Autistic Disorder; Bacterial Meningitis; Bacterial Septicemia; Benzodiazepine; Bipolar Disorder; Bone and Joint Infections; Central Nervous System Infections; Convulsions; Cytomegalovirus Retinitis; Early-onset Schizophrenia Spectrum Disorders; Epilepsy; General Anesthesia; Gynecologic Infections; Herpes Simplex Virus; Infantile Hemangioma; Infection; Inflammation; Inflammatory Conditions; Intra-abdominal Infections; Lower Respiratory Tract Infections; Migraines; Pain; Pneumonia; Schizophrenia; Sedation; Seizures; Skeletal Muscle Spasms; Skin and Skin-structure Infections; Treatment-resistant Schizophrenia; Urinary Tract Infections; Withdrawal; Sepsis; Gram-negative Infection; Bradycardia; Cardiac Arrest; Cardiac Arrhythmia; Staphylococcal Infections; Nosocomial Pneumonia; Neuromuscular Blockade; Methicillin Resistant Staphylococcus Aureus; Endocarditis; Neutropenia; Headache; Fibrinolytic Bleeding; Pulmonary Arterial Hypertension; CMV Retinitis; Hypertension; Chronic Kidney Diseases; Hyperaldosteronism; Hypokalemia; Heart Failure; Hemophilia; Heavy Menstrual Bleeding; Insomnia
Intervention: Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Sponsors: Daniel Benjamin; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); The EMMES Corporation
Recruiting - Condition: Diabetic Macular Edema
Interventions: Drug: Brolucizumab; Drug: Aflibercept
Sponsor: Novartis Pharmaceuticals
Recruiting - Conditions: Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic); Leptin Receptor Deficiency Obesity; Bardet-Biedl Syndrome; Alstrom Syndrome; Smith-Magenis Syndrome
Intervention: Drug: Setmelanotide
Sponsor: Rhythm Pharmaceuticals, Inc.
Recruiting - Condition: Adenoviral Conjunctivitis
Interventions: Drug: SHP640; Drug: PVP-I 0.6%; Drug: Placebo
Sponsor: Shire
Recruiting - Conditions: Opsoclonus Myoclonus Syndrome; Neuroblastoma
Interventions: Drug: Dexamethasone acetate; Drug: dexamethasone and cyclophosphamide; Drug: dexamethasone and rituximab
Sponsor: Institut Curie
Recruiting - Condition: Melanoma, Ocular
Intervention: Combination Product: Melphalan/HDS
Sponsors: Delcath Systems Inc.; IQVIA Biotech
Recruiting
Clinical Trial Locations